The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics’ Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
This article was originally published on MedicalXpress.com